50 results about "Cell Surface Proteins" patented technology

Provided are compositions containing a conjugate containing a phthalocyanine dye, including compositions containing stabilizing agents, such as non-ionic surfactants and / or protectants. In some aspects, the compositions result reduced aggregation of the conjugate due to agitation, temperature exposure, and / or pH. Also provided are articles of manufacture containing the compositions containing the conjugates, and methods for their administration to subjects for photoimmunotherapy. In some embodiments, the phthalocyanine dye conjugates are conjugated to a targeting molecule, such as an antibody, that targets the conjugate to a cell or pathogen, such as by binding to a cell surface protein.

Provided are methods for manufacturing a conjugate containing a phthalocyanine dye, including methods that include one or more steps of preparing or producing the conjugate, formulating the conjugate and packaging the conjugate. In some aspects, the manufacturing methods result in the generation of a stable conjugate. Also provided are stable phthalocyanine dye conjugates, compositions and articles of manufacture containing the stable conjugates, and methods for their administration to subjects for photoimmunotherapy. In some embodiments, the phthalocyanine dye conjugates are conjugated to a targeting molecule, such as an antibody, that targets the conjugate to a cell or pathogen, such as by binding to a cell surface protein.

CD318 (CDCP1) is a CUB-domain containing cell surface protein over-expressed in major types of cancers to promote tumor growth and metastasis. The present disclosure relates to the identification and characterization of novel anti-CD318 monoclonal antibodies. By targeting CD318 as a tumor associated antigen, the disclosure further relates to different modalities of using anti-CD318 antibodies to kill cancer cells, including CD318 antibody based immunocytokines, CD318 antibody-based immune modulators, and CD318 antibody drug conjugates.

The invention relates to the technical field of cell analysis, and discloses a cell analysis method, a cell analysis device and a storage medium, and the method comprises the following steps: S1, multi-modal labeling: synchronously loading cell surface protein, a metabolism probe and a spatial positioning marker; s2, collaborative acquisition: obtaining space-time multi-dimensional data through flow type, mass spectrum and two-photon combination; s3, tensor modeling: constructing four-dimensional data and correcting spatial drift; s4, metabolic constraint decomposition: executing non-negative tensor decomposition to obtain a factor matrix; s5, dynamically adjusting parameters: optimizing excitation and sampling frequencies in real time according to factor changes; and S6, feature analysis: calculating a metabolism-phenotype coupling index. Through a multi-modal synchronous marking and four-dimensional dynamic tensor modeling method, cross-dimensional association of physical characteristics, molecular expression and metabolic activity is broken through, lossless fusion of single-cell multi-dimensional data is realized, and the spatial resolution is greatly improved compared with the prior art.

The invention provides a three-specificity immune cell adapter-cytokine fusion protein for malignant tumor immunotherapy as well as a preparation method and application of the three-specificity immune cell adapter-cytokine fusion protein. The fusion protein comprises a first binding domain, a second binding domain and a cytokine structural domain which are covalently linked to form a single polypeptide chain or polypeptide compound. The first binding domain is specifically bound with a tumor associated antigen, and the target spot of the first binding domain comprises but is not limited to KK-LC-1, MSLN, HER2, Claudin18.2, Claudin6 and PSMA; the second binding domain is specifically bound with a CD3 protein complex on the surface of the T cell; the cytokine domain is IL2, IL15, IL12, IL21 or a functional variant thereof. The invention also relates to a nucleic acid molecule for coding the fusion protein, an expression vector and application thereof. The fusion protein can be used for immunotherapy of malignant tumors such as colon cancer, gastric cancer, breast cancer, liver cancer, lung cancer and cervical cancer, and has a good application prospect. The invention effectively solves the problems of insufficient T cell activation and limited killing in solid tumor immunotherapy in the prior art.

Methods, compositions, and systems for treating various cancers are disclosed. The disclosed compositions may include a poly peptide with affinity for a CD99 cell surface protein. Disclosed polypeptides may comprise a sequence selected from GYYMH, RINPYTGATTYNQIFKD, YYYGNNYNVYLDY, SASQGISNYLS, YTSTLHIS, and QQYSNLPWT, and may include mouse, human, or humanized peptide sequences. In many embodiments, the polypeptides may be immunoglobulins, for example IgG3 or IgG4. The disclosed polypeptides may be administered to a subject having a cancer cell with elevated expression of CD99. In some embodiments, the subject may be suffering from cancer, including diffuse intrinsic pontine glioma (DIPG). Ewing Sarcoma, acute myeloid leukemia (AML), ependymoma, or neuroblastoma. Treatment methods include administering the disclosed polypeptides to a subject that may also be treated with radiation. Disclosed herein are systems for treating one or more cancers. The systems may comprise a radiation source, for example a medical fractionated radiation source.

The present application relates to a compositions and methods comprising or expressing a hevamine A-related MoMo30 protein from Momordica balsamina. The MoMo30 protein is about 30 kDa in size, is stable after being autoclaved at 120° C. for 30 min, resists proteolytic cleavage by trypsin, exhibits mannose-sensitive binding to HIV gp120, exhibits hemagglutinin and chitinase activity, is capable of activating and stimulating T cell proliferation, is capable of preventing infection by HIV-1 or alleviating symptoms in an HIV-1 infected patients, and comprises an amino acid sequence of SEQ ID NO: 4. The MoMo30 protein and / or a nucleic acid encoding the same may be used in methods for preventing or treating microbial infections by HIV, SARS-CoV-2 and other enveloped viruses, as well as other microorganisms comprising cell surface proteins containing glycan residues, such as mannose.

Disclosed herein are immune cells (Bisuper Cells, BS-Cells) that have been engineered to express an immune cell activator polypeptide comprising an extracellular marker domain and incorporate the polypeptide into the cell membrane surface. Also disclosed are immune cells engineered to secrete one or more polypeptide effector molecules, and immune cells engineered to express both molecules. Nucleic acid vectors for expressing these molecules in immune cells are disclosed. Also disclosed are bispecific polypeptides that can be used to specifically bind immune cells expressing immune cell activator polypeptides to another cell. Also disclosed are systems comprising both immune cells and various bispecific polypeptides that can bind to different cell surface proteins of the same or different target cells, e.g., that can be used to expand immune cells in vivo and treat various tumors.

The present invention relates to a computer-implemented method for obtaining, by training, a tuned model configured to predict whether a protein is present at least partially on the external surface of a cell, a computer-implemented method for determining whether a protein is at least partially present on the external surface of a cell, a computer-implemented method for forming a dataset for obtaining, by training, the tuned model, and a system comprising a processor coupled to a memory and preferably a graphical user interface, the memory having recorded thereon the computer program comprising instructions for performing any of the computer-implemented methods.

The present invention relates to NK cells expressing dual-targeting chimeric antigen receptors for CD19 and CD22, and uses thereof. In the present invention, it was found that the delivery efficiency of a CAR expression vector and the production efficiency of CAR-NK cells are excellent when, among the cell surface proteins of PBMCs for producing CAR-NK cells (UCI-101), CD16 is expressed at 70% or less, natural killer group 2D (NKG2D) is expressed at less than 10%, CD57 is expressed at 30% or less, low-density lipoprotein receptor (LDLR) is expressed at 0.1% or more, and natural cytotoxicity triggering receptor 3 (NKp30) is expressed at less than 10%. In addition, optimal conditions for inducing NK cell differentiation and optimal conditions for transduction, under which the delivery efficiency of a CAR expression vector and the production efficiency of CAR-NK cells are excellent, were established, and CAR-NK cells produced by the method according to the present invention were found to exhibit an excellent antitumor effect in an animal model, and thus can be effectively used as a composition for preventing or treating diseases related to CD22 (or CD19) expression or diseases related to B cells.

A rapid detection method for cytotoxic T cells in peripheral blood. The method enables rapid identification of cytotoxic T cells in peripheral blood by detecting the expression of T-cell surface protein CX3CR1, or CX3CR1 and GPR56. The detection method is rapid in operation, does not involve cell fixation and permeabilization, and does not affect cell activity.

The application relates to preparation and application of anti-CD38 rabbit recombinant monoclonal antibodies, the obtained antibodies have good specificity, most importantly, the antibodies have high affinity and can recognize natural cell surface CD38 proteins, and can be used for flow, ELISA and immunohistochemical detection applications.

Provided is a novel compound useful for, e.g., comprehensive analysis of cell surface proteins. Disclosed is a functional compound or a salt thereof in which a tyrosine residue reaction site R is linked to a protein purification tag site Tag via a spacer S. The tyrosine residue reaction site R is a group represented by formula (1). (In the formula, * denotes a bond with a spacer S, and R1 and R2 are each independently selected from the group consisting of H, alkyl which optionally be substituted with one or more substituents, aryl which optionally be substituted with one or more substituents, and heteroaryl which optionally be substituted with one or more substituents.)

The present disclosure provides methods and compositions for using a novel class of glycan conjugates for modulating cell surface proteins and receptor complexes that can be used to engage signaling pathways within desired cell types. Such defined cell-targeting bioactive glycoligands are directed to cell engagement and activation in therapeutic applications.

Genetically engineered cells (e.g., HSPCs or T cells), such as hematopoietic stem cells, having one or more genetically edited genes of cell-surface proteins, and therapeutic uses thereof, either alone or in combination with immune therapy that targets the cell-surface protein(s).

The application provides a method for separating and purifying cell surface proteins and application thereof. The method comprises the following steps: culturing cells to be separated, adding an azide solution to the cells for incubation, then adding a Tris-HCl buffer to terminate the reaction, so as to label the cell surface proteins with azides; then adding a TNTE buffer and a protease inhibitor to lyse the cells, centrifuging to obtain cell lysates labeled with azides; incubating the cell lysates labeled with azides with phosphine-biotin-streptavidin magnetic beads, so as to enrich the cell surface proteins labeled with azides, and obtain magnetic beads containing the cell surface proteins. The method can effectively separate the cell surface proteins, has low background, high efficiency and good repeatability, and can be applied to quantitative analysis of cell surface proteomes.

A transkingdom platform for the delivery of therapeutics to target cells. The system maintains the export and uptake functions of Inv while modifying its targeting away from β1 integrin to other proteins expressed on the surface of target eukaryotic cells (i.e., a cell surface protein) or chemical moieties (i.e., a cell surface chemical moiety) expressed on the surface of a target eukaryotic cell by replacing D4 and D5 of Inv with a binding domain from a heterologous protein via genetic engineering. These heterologous proteins could be derived from bacterial, fungal, animal, or viral genomes. This engineering would result in the construction of a chimeric Inv protein in which D1-D3 (i.e., the non-binding domains) are fused in frame to an alternative binding domain derived from a heterologous protein. The alternative binding domain would interact with a different cell surface protein or chemical moiety, which can in some instances be referred to as a receptor, on the surface on the surface of a eukaryotic cell, thereby allowing specific targeting to cells independent of Inv's intrinsic β1 integrin binding.

Therapeutic compounds for inhibiting and reducing expression of cell surface proteins, and methods of treating cancer, inflammation, and diabetes using the same.

Tumor cell identification is of great importance for cancer diagnosis, which is mainly focused on the identification of cell surface proteins. In this work, we demonstrate that high specificity can be achieved by integrating cell surface proteins and dual miRNAs to design sensors. DNA tetrahedron sensors are designed by assembling an aptamer, two miRNA complementary sequences and multiple complementary strands. The aptamer is specific to the membrane protein of tumor cells. The two complementary miRNA sequences are used to construct an AND logic signal output in response to the dual miRNAs in cells. Only when the membrane protein and the dual miRNAs exist simultaneously, the sensor can work in cells with high specificity. By imaging different types of membrane proteins and cancer cells with different expression of dual miRNAs, the DNA tetrahedron sensor has excellent accuracy in imaging analysis of target tumor cells.

Tumors use a variety of mechanisms to avoid the host's anti-tumor immune response. Humoral immune suppression is one of the mechanisms. Tumors produce circulating factors that can suppress antibody or complement-mediated immune responses to enhance their own survival. Mesothelin is a cell surface protein that is overexpressed by several cancer types that are associated with a microenvironment that exhibits immune suppression. Anti-mesothelin antibodies often suffer from such immune suppression microenvironments. However, an alternatively formatted anti-mesothelin antibody is effective in killing mesothelin-expressing cancers, independent of the tumor microenvironment immune status.

The invention relates to compositions and methods for cell therapy. Provided are lentiviral vectors comprising, in operable linkage, sequences encoding a Chimeric Antigen Receptor (CAR), a peptide linker, and a tag suitable for detection, selection, or depletion. The CAR comprises an extracellular antigen binding domain, a transmembrane domain, and intracellular signaling domains. The tag, positioned C-terminally or N-terminally to the linker, facilitates detection and / or selection of host cells expressing the CAR. In certain embodiments, the tag comprises a truncated, non-functional cell surface protein (e.g., hEGFRt) usable as a safety switch for in vivo depletion via cognate binding agents (e.g., antibodies). Also provided are genetically engineered host cells (e.g., T cells, NK cells) transduced with said vectors, pharmaceutical compositions comprising such cells, methods for their manufacture, and methods for treating diseases, such as cancer, using said compositions.

The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein. The present disclosure also relates to agents capable of binding to a receptor on a surface of a pathogenic cell and inducing the depletion of the pathogenic cell in a subject for use in the treatment of cancer, inflammatory diseases, autoimmune diseases, viral infection, or bacterial infection.

The present invention provides compositions and methods related to the cell surface protein CRB1 for the treatment of retinopathies in a subject. In particular, isolated polynucleotides and recombinant vectors encoding a particular isoform called Crumbs 1-B (CRB1-B) are provided. The CRB1-B encoding polynucleotides may be operably linked to a heterologous promoter capable of expressing the isoform in a retinal cell. Kits employing such compositions are also provided.

The present invention relates to the treatment of cancer. In this study, the inventors focused on evaluating the efficiency of SIS3 in cancer treatment concurrently with identifying genes driving resistance to SMAD3 inhibition, aiming to find efficient and long-lasting treatment options. Novel high-throughput methods such as CRISPR-screen and long-read RNA sequencing were used to identify and precisely characterise the genes and signalling pathways driving resistance to SMAD3 inhibition. They identified a cell surface protein SLC16A1 / MCT1 as a driver of resistance to SIS3. They demonstrated that loss of MCT1 by CRISPR-Cas9 KO or inhibition by a specific inhibitor AZD3965 results in higher sensitivity to SMAD3 inhibition. To study if the effect is common to other similar cancer types, they also overexpressed MCT1 in KRAS-mutated lung adenocarcinoma cells and observed higher resistance to the inhibitory effect of SIS3. Synergistic inhibition of SMAD3 and MCT1 resulted in efficient melanoma cell death in a dose-dependent manner, suggesting the use of combined inhibition to be a beneficial treatment option for cancer. Thus, the present invention relates to a combination of a SLC16A1 inhibitor and a SMAD3 inhibitor for use in the treatment of a cancer in a subject in need thereof.

Disclosed herein are methods, systems, and compositions for enhancing the effectiveness of β-cell (Beta-cell)-based therapies. Also disclosed herein are methods, systems, and compositions related to identifying, sorting and separating heterogeneous populations of stem cell-derived pancreatic β-cells (sBCs) into more useful and functionally homogeneous cell populations. In many embodiments, the most mature and functional of the sBCs are identified and live-sorted using the cell surface protein Ectonucleoside Triphosphate Diphosphohydrolase-3 (ENTP3), which is also referred to as CD39L3. The presently disclosed methods, systems, and compositions are useful for cell therapies, for example replacement therapy. In many embodiments the disclosed systems, methods, and compositions are useful in treatments for diabetes. In some embodiments, the disclosed methods, systems, and compositions may be useful in treating, preventing, and / or curing diabetes, for example type-1 diabetes.

Polypeptide constructs directed against the CD4+ T-cell surface proteins and HIV Env proteins are disclosed. These constructs may be used to treat and prevent HIV infection and to prevent the entry of HIV into mammalian cells.

The application relates to preparation and application of anti-CD22 rabbit recombinant monoclonal antibodies. The obtained antibodies have good specificity, and most importantly, the antibodies have high affinity and can recognize natural cell surface CD22 proteins, and can be used for flow and ELISA detection applications.

The present invention provides compositions and methods related to the cell surface protein CRB1 for the treatment of retinopathies in a subject, as well as systems and kits employing such compositions.

This disclosure relates to immunogenic compositions comprising Borrelia cell surface protein A (OspA) antigen or RNA polynucleotide encoding the OspA antigen, and an adjuvant. In some embodiments, the immunogenic compositions are suitable for stimulating an immune response to Borrelia in a subject. This disclosure also relates to kits of immunogenic compositions, their use, and methods of using them.

The present invention relates to: a fusion protein comprising a mitochondrial outer membrane anchoring peptide and a cerebrovascular endothelial cell surface protein binding site; modified mitochondria to which the fusion protein is bound; and a pharmaceutical composition comprising the modified mitochondria as an active ingredient. The modified mitochondria comprising the cerebrovascular endothelial cell surface protein binding site according to the present invention can pass through the blood-brain barrier at the cellular and animal level. In addition, administering the modified mitochondria to a Parkinson's disease mouse model can alleviate movement disorders. Therefore, the modified mitochondria according to the present invention can be used as a therapeutic agent for brain diseases caused by mitochondrial dysfunction.